An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism
Authors' conclusion
Eneboparatide allowed independence from conventional therapy and maintenance of serum calcium within a target range while normalizing uCa excretion and producing a balanced resumption of bone turnover.
Study context
- Population
- Patients with chronic hypoparathyroidism (HP); 21 women, 7 men; mean age 58 years (range 28–72)
- Participants
- 28 patients
- Comparison
- Eneboparatide starting dose 20 µg/day vs 10 µg/day
- C1n = 12
- C2n = 16
- Outcome
- Proportion of patients achieving independence from conventional therapy
- Follow-up
- 3 months
Methodological details2 consecutive cohorts
- 2 consecutive cohorts
Main finding
As reported in the abstract
Independence from conventional therapy
Patients achieving independence from conventional therapy
≥ 88%
Further findings
24-h urine calcium
- Rapid and sustained reduction of mean 24-h urine calcium (uCa), even in patients with hypercalciuria
Bone turnover markers and bone mineral density (BMD)
- Bone turnover markers slightly increased; BMD unchanged
Safety
- Eneboparatide was well tolerated with no serious adverse events (AEs)
Original publication
An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism. J Clin Endocrinol Metab. Published 6 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →